Stock Markets June 24, 2026 09:40 AM

Italgas Shares Slip After Equita Downgrade and Lack of Near-Term Catalysts

Analyst cut and a cautious market leave the Italian gas distributor vulnerable as investors digest its 2032 plan and valuation

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
IG

Italgas stock fell 2.6% to €10.18, dragged lower after Equita downgraded the shares from Buy to Hold and flagged limited upside given current valuation and tender-related investment challenges. The downgrade, a trimmed 2032 EBITDA estimate and a risk-off tone across European equities combined to weigh on the stock amid an absence of immediate earnings catalysts ahead of late July results.

Italgas Shares Slip After Equita Downgrade and Lack of Near-Term Catalysts
IG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Equita downgraded Italgas from Buy to Hold and cited limited upside at current valuation.
  • Analyst trimmed 2032 EBITDA to €3.2 billion versus the company’s €3.3 billion target, implying roughly 8% adjusted annual EPS growth.
  • Broader European risk-off sentiment and the FTSE MIB’s correction contributed to selling pressure; peers Snam and Terna outperformed Italgas.

Shares of Italgas declined 2.6% to trade at €10.18, extending a several-session pullback from a session peak of €10.455. The slide accelerated after brokerage Equita moved the stock from Buy to Hold, citing constrained upside at the current valuation.

Equita highlighted a €2.4 billion investment target connected to gas tenders as a difficult objective to reach and lowered its 2032 EBITDA projection for the company to €3.2 billion. That estimate sits slightly below Italgas's own €3.3 billion target and reflects an implied adjusted annual EPS growth rate of about 8%.

Investors also had the company’s recently disclosed strategic plan through 2032 to consider. Italgas outlined a plan incorporating €13 billion of investments and forecasting an 8.4% compound annual growth rate for EBITDA. That announcement came during the prior session’s sell-off and did not trigger a sustained recovery, as market conditions remained unfavorable.

Valuation and catalyst gap

Market participants noted that the stock carries a relatively high valuation against consensus price targets. With no near-term earnings catalysts before the company reports next results in late July, Italgas has been more exposed to market volatility. The absence of upcoming company-specific positive triggers has reinforced sensitivity to broader market movements.

Wider market backdrop

European equities traded lower in the session, with the FTSE MIB down 0.54% as the index extended a correction following losses in the previous two sessions. Defense-related stocks were among the weakest after Germany cancelled a major frigate construction contract. The prior session had fallen 1.08%, a drop explained in part by dividend-related adjustments and technology sector weakness spilling over from Wall Street.

Within Italy’s benchmark, Italgas ranked among the more pronounced decliners and underperformed peers such as Snam and Terna. The stock touched a session low of €10.18 as sellers dominated through the afternoon, reflecting a combination of the analyst downgrade, elevated valuation considerations and a broadly risk-off mood on European bourses.


Bottom line

Equita’s downgrade - together with its trimmed 2032 EBITDA forecast and doubts about the €2.4 billion tender-linked investment goal - has reduced the immediate upside case for Italgas. Coupled with an absence of imminent company-specific catalysts and a negative tone in the FTSE MIB, these factors left the stock vulnerable during the trading session.

Risks

  • Execution risk tied to the €2.4 billion investment target linked to gas tenders - impacts the utilities and energy sectors.
  • Valuation risk as the stock trades relatively high versus consensus price targets - increases sensitivity to market swings in equities.
  • Lack of near-term earnings catalysts before late July results - heightens vulnerability to broader market corrections.

More from Stock Markets

Quest Diagnostics Gains After New York Clears Haystack MRD Test for Nationwide Use Jun 24, 2026 Put Options Drive Heavy Activity in Stellantis Contracts; Total Volume Tops 34,000 Jun 24, 2026 Warsaw Stocks Slip; WIG30 Falls 2.31% to One-Month Low Jun 24, 2026 Copenhagen benchmark rises as consumer and healthcare names lead gains Jun 24, 2026 Istanbul shares retreat as technology, textile and chemical stocks drag BIST 100 down 1.43% Jun 24, 2026